Videos From Series
Educational Objectives:
- Review the risk factors for glaucoma and the impact of increased intraocular pressure (IOP) on patient outcomes
- Discuss the current use of existing and novel pharmacotherapies for patients with open angle glaucoma
- Evaluate the clinical trials results of newly approved ocular hypotensive agents, including ROCK inhibitors and combination agents
Chair and Moderator:
Leon W. Herndon Jr., MD
Professor of Ophthalmology
Chief, Glaucoma Division
Duke Eye Center
Durham, NC
Speaker:
Jonathan Myers, MD
Chief, Glaucoma Service
Wills Eye Hospital
Philadelphia, PA